XOOMAR

RenovoRx (RNXT)

RenovoRx on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.

Download CSV

865K

Short interest

settlement 2026-10-15

1.6

Days to cover

unchanged vs prior

85.0%

Short share of volume

2026-11-03

5,081

Fails to deliver

settlement 2026-09-28

Thu 12 Nov

Next earnings

estimated date

$0

Insider flow, 90 days

0 buys, 0 sells

As of 2026-11-03.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in RNXT is 864,570 shares, up 191,012 shares over the last month. Over the last 48 readings it ranged from 71,850 shares (31 October 2024) to 946,982 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 528K shares a day that is 1.6 days to cover.

Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rnxt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-10-15864,570-8.7%528,2581.64
2026-09-30946,982+40.6%597,3511.59
2026-09-15673,558+55.6%2,055,8131.00
2026-08-31432,726-35.8%903,8721.00
2026-08-14674,017+137.8%553,3381.22
2026-07-31283,437-13.6%197,1051.44
2026-07-15327,868-5.2%195,5411.68
2026-06-30345,817-1.0%246,4611.40
2026-06-15349,247-16.1%302,4951.15
2026-05-29416,166+8.4%340,2571.22
2026-05-15384,039-24.1%265,9291.44
2026-04-30505,892+7.4%309,8591.63
2026-04-15470,946-20.8%290,6091.62
2026-03-31594,804-3.7%643,7291.00
2026-03-13617,404+41.9%304,2302.03
2026-02-27435,099-2.0%158,8432.74
2026-02-13444,056-20.6%168,8012.63
2026-01-30559,162+3.3%222,6322.51
2026-01-15541,448+28.9%473,4071.14
2025-12-31419,908-5.3%206,9762.03
2025-12-15443,579+16.0%184,7662.40
2025-11-28382,383-43.5%288,3701.33
2025-11-14676,264+7.6%451,0931.50
2025-10-31628,461+2.4%326,8121.92
2025-10-15613,527+524.4%807,0351.00
2025-09-3098,257-64.1%654,9551.00
2025-09-15273,549+38.1%992,0441.00
2025-08-29198,095+47.4%186,4441.06
2025-08-15134,441+54.9%273,7581.00
2025-07-3186,806-26.0%98,5851.00
2025-07-15117,308-37.4%120,0061.00
2025-06-30187,493+34.8%184,3621.02
2025-06-13139,075-18.0%164,1671.00
2025-05-30169,612-35.4%290,3221.00
2025-05-15262,375+4.8%115,2342.28
2025-04-30250,265-15.2%112,9922.21
2025-04-15295,074+12.1%116,9912.52
2025-03-31263,207+39.1%95,3532.76
2025-03-14189,155-19.6%46,9074.03
2025-02-28235,192+14.2%130,1801.81
2025-02-14205,910+60.7%339,5411.00
2025-01-31128,115-1.6%150,5171.00
2025-01-15130,183+12.7%50,0122.60
2024-12-31115,525+57.8%71,9261.61
2024-12-1373,229-17.3%117,6591.00
2024-11-2988,522+1.8%119,0441.00
2024-11-1586,949+21.0%29,3152.97
2024-10-3171,850-21.8%24,6562.91

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 3 November 2026, the short share of RNXT volume is 85.0%, up 6.2 points over the last five sessions. Over the last 30 readings it ranged from 35.5% (20 October 2026) to 85.0% (3 November 2026). The latest reading sits at the top of that range. The latest reading is 32.5 points above the 30-session average of 52.5%, on 119K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-11-03101K119K85.0%0
2026-11-02113K170K66.5%35,622
2026-10-30143K233K61.5%9,229
2026-10-29133K222K60.0%4,100
2026-10-2858K91K63.7%425
2026-10-27146K186K78.8%100
2026-10-2657K98K58.6%0
2026-10-23134K193K69.5%0
2026-10-2287K151K57.6%0
2026-10-21184K245K75.0%3,387
2026-10-2046K130K35.5%2,000
2026-10-1982K144K57.4%250
2026-10-1683K181K46.1%10,200
2026-10-1595K170K56.0%2,001
2026-10-14154K340K45.3%0
2026-10-13197K481K40.9%730
2026-10-1273K169K43.0%10,000
2026-10-09222K423K52.4%1,139
2026-10-08113K277K40.8%8,948
2026-10-07147K350K42.0%9,000
2026-10-06148K322K46.0%15,600
2026-10-05159K376K42.3%0
2026-10-0255K128K43.1%0
2026-10-01119K205K58.2%5,250
2026-09-3072K201K36.0%4,700
2026-09-2982K183K45.0%4,953
2026-09-28221K504K43.8%8,000
2026-09-25106K297K35.7%0
2026-09-24137K277K49.3%450
2026-09-23161K395K40.8%6,286

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 28 September 2026, the fails-to-deliver balance in RNXT is 5,081 shares, unchanged over the last settlement date. Over the last 30 readings it ranged from 1 share (26 May 2026) to 47,251 shares (8 September 2026).

SettlementShares failedPriceValue
2026-09-285,081$1.66$8K
2026-09-255,081$1.68$9K
2026-09-2421,705$1.63$35K
2026-09-2321,705$1.70$37K
2026-09-2221,705$1.67$36K
2026-09-213,585$1.69$6K
2026-09-17970$1.55$2K
2026-09-161,020$1.72$2K
2026-09-151,250$1.69$2K
2026-09-14120$1.76$211
2026-09-0847,251$2.39$113K
2026-09-0420,298$2.37$48K
2026-08-2813,500$1.48$20K
2026-08-144,431$1.26$6K
2026-08-0710,000$1.15$12K
2026-08-0412,700$1.06$13K
2026-07-177,187$0.88$6K
2026-07-09123$0.90$111
2026-06-264,480$0.93$4K
2026-06-241,510$0.91$1K
2026-06-23453$0.91$412
2026-06-15669$0.84$562
2026-06-11546$0.85$464
2026-05-273,349$0.92$3K
2026-05-261$0.88$1
2026-05-2158$0.81$47
2026-05-1992$0.78$72
2026-05-184,437$0.82$4K
2026-05-053,284$0.89$3K
2026-04-3039,462$0.83$33K

Insider trades

SEC Form 4, newest first. JSON

No open-market insider trades were reported for RNXT in the last 90 days. The most recent filings are listed below. Latest filing: VOLL MARK (Chief Financial Officer) on 2026-09-10.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-09-10VOLL MARKChief Financial OfficerGrant80K$0.00$0222K
2026-05-19VOLL MARKChief Financial OfficerBuy25K$0.79$20K142K
2026-04-03VOLL MARKChief Financial OfficerGrant80K$0.00$0117K
2026-03-25VOLL MARKChief Financial OfficerGrant12K$0.00$037K
2026-03-20VOLL MARKChief Financial OfficerBuy97Kprice not stated in the filingnot stated97K
2026-03-20Bagai ShaunChief Executive OfficerBuy24Kprice not stated in the filingnot stated313K
2026-03-20Marton LaurenceDirectorBuy10Kprice not stated in the filingnot stated10K
2026-01-21Agah RamtinChief Medical OfficerBuy10K$1.00$10K798K
2025-12-31Agah RamtinChief Medical OfficerBuy10K$0.86$8K788K
2025-12-30Agah RamtinChief Medical OfficerBuy205$0.83$169779K
2025-12-18Bagai ShaunChief Executive OfficerBuy5K$0.90$5K340K
2025-12-17Bagai ShaunChief Executive OfficerBuy5K$0.85$4K335K
2025-12-16Agah RamtinChief Medical OfficerBuy12K$0.85$10K778K
2025-12-05Agah RamtinChief Medical OfficerBuy10K$0.96$10K766K
2025-11-24Agah RamtinChief Medical OfficerBuy12K$0.80$10K756K
2025-11-21Agah RamtinChief Medical OfficerBuy10K$0.80$8K744K
2025-08-25Bagai ShaunChief Executive OfficerBuy5K$0.91$5K330K
2025-08-22Bagai ShaunChief Executive OfficerBuy5K$0.95$5K325K
2025-06-05Agah RamtinChief Medical OfficerBuy21K$1.40$29K734K
2025-05-02Marton LaurenceDirectorExercise or conversion20K$0.15$3K66K
2025-04-22Agah RamtinChief Medical OfficerGift400K$0.00$0713K
2025-04-15Bagai ShaunChief Executive OfficerBuy8K$0.91$7K320K
2025-04-15Agah RamtinChief Medical OfficerBuy15K$0.90$14K1.1M
2025-04-11Agah RamtinChief Medical OfficerBuy20K$0.80$16K1.1M
2025-04-10Kocak RonVP Controller and PAOBuy7K$0.79$5K13K
2025-04-09Bagai ShaunChief Executive OfficerBuy10K$0.83$8K313K
2025-04-09Agah RamtinChief Medical OfficerBuy30K$0.81$24K1.1M
2025-04-09Kocak RonVP Controller and PAOBuy6K$0.80$5K6K
2025-04-08Agah RamtinChief Medical OfficerBuy26K$0.84$22K1.0M
2025-04-08Marton LaurenceDirectorBuy12K$0.85$10K46K
2025-04-08Kocak RonVP Controller and PAOBuy95$0.80$7695
2025-04-07Bagai ShaunChief Executive OfficerBuy10K$0.83$8K303K
2024-01-26Macfarlane K. AngelaDirectorBuy41K$1.22$50K41K
2024-01-26Marton LaurenceDirectorBuy8K$1.22$10K34K
2024-01-26Bagai ShaunChief Executive OfficerBuy41K$1.22$50K293K
2024-01-26Spiegel Robert J.DirectorBuy41K$1.22$50K41K
2024-01-26Agah RamtinChief Medical OfficerBuy41K$1.22$50K47K
2023-10-03Nelms AngelaChief Operating OfficerBuy300$1.05$315300
2023-10-03Nelms AngelaChief Operating OfficerBuy800$1.05$8401K
2022-11-03Marton LaurenceDirectorExercise or conversion25K$1.70$43K25K
2022-06-07Agah RamtinChief Medical OfficerBuy5K$1.93$10K6K
2022-05-19Bagai ShaunChief Executive OfficerBuy6K$2.05$11K252K
2022-04-22RYAN UNA SDirectorOther transaction27K$0.93$25K81K
2022-04-22RYAN UNA SDirectorOther transaction16K$1.62$26K97K
2022-03-16Agah RamtinChief Medical OfficerGift975K$0.00$0975K
2022-03-16Agah RamtinChief Medical OfficerGift975K$0.00$01K
2022-03-03RYAN UNA SDirectorOther transaction6K$3.95$25K54K
2022-03-03RYAN UNA SDirectorOther transaction48K$4.19$200K48K
2021-08-30Agah RamtinChief Medical OfficerConversion1Kprice not stated in the filingnot stated976K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

2 holders report 5% or more of RNXT in their latest filing, all on Schedule 13G (passive). The largest reported stake is Orin Hirschman at 9.8% of the class (4,430,439 shares), filed 2026-04-27 for an event on 2026-03-31.

FiledFormHolderSharesOf classEvent
2026-04-2713G/Ano. 3Orin Hirschmanparent holding company, individual4.4M9.8%2026-03-31
2026-04-2713G/Ano. 3AIGH Capital Management LLCinvestment adviser, other entity4.4M9.8%2026-03-31
2025-11-1313G/Ano. 2AWM Investment Company, Inc.investment adviser864K2.4%2025-09-30

13F holders

Tracked managers holding RNXT at their latest 13F. JSON

2 of the 30 tracked managers held RNXT at their latest 13F, $142K in total at quarter-end prices. Citadel Advisors is the largest at $131K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 2 cut.

FundQuarterSharesValueOf portfolioChange in shares
Citadel Advisors2026-06-30134K$131K0.00%-99K
Renaissance Technologies2026-06-3011K$11K0.00%-2K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

RenovoRx in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows RenovoRx (RNXT), SEC CIK 1574094, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest
FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-28.JSON and CSV
Large holders
SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-27.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates
SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
Insider trades
SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-10.JSON and CSV
Company record
EDGAR filing index for CIK 1574094Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
10 requests a minute without a key, 30 with a free key from a free account.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Datasets

Frequently Asked Questions

How much of RNXT is sold short?
864,570 shares were held short at the 2026-10-15 settlement, 1.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is RNXT's daily short volume?
On 2026-11-03, 100,863 of the 118,678 RNXT shares reported to FINRA were sold short, 85.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does RNXT have fails to deliver?
The SEC's latest file shows 5,081 RNXT shares failed to deliver at settlement 2026-09-28. Fails are reported per settlement date and published twice a month with a lag.
Are RNXT insiders buying or selling?
No open-market insider trades were reported for RNXT in the last 90 days. The most recent filings are listed below. Latest filing: VOLL MARK (Chief Financial Officer) on 2026-09-10.
Who owns 5% or more of RNXT?
2 holders report 5% or more of RNXT in their latest filing, all on Schedule 13G (passive). The largest reported stake is Orin Hirschman at 9.8% of the class (4,430,439 shares), filed 2026-04-27 for an event on 2026-03-31.
Which tracked 13F managers own RNXT?
2 of the 30 tracked 13F managers held RNXT shares at their latest filing, $142K in all. The largest: Ken Griffin's Citadel Advisors (134K shares, $131K), Renaissance Technologies (11K shares, $11K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.